Friday, 1 August 2014

Annual diabetes checks among indicators proposed for latest NICE QOF menu

A series of annual checks to monitor and improve the health of people with diabetes are among measures proposed by NICE for its latest Quality and Outcomes Framework (QOF) indicator menu (NICE)


Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

Raised glucose concentration is a modifiable risk factor for ischaemic heart disease in middle-aged people with type 2 diabetes and other cardiovascular risk factors (The Lancet Diabetes & Endocrinology)


High or low calcium intake increases cardiovascular disease risks in older patients with type 2 diabetes

Patients whose Ca intake was high or low (81.2%) had significantly higher C-reactive protein (CRP) than those whose Ca intake was moderate (Cardiovascular Diabetology)


New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin, but with consistently less risk of nocturnal hypoglycemia (Diabetes Care)


Comparison of the effects on glycaemic control and ß-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)

All three agents showed efficacy regarding glycaemic control and metabolic benefits; however, exenatide showed the greatest efficacy. ß-cell function improved in all treatment groups, hence early initiation of ß-cell-protective therapy may halt the decline in ß-cell function in type 2 diabetes (Journal of Internal Medicine)

No comments:

Post a Comment